The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...

PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE ...

An immunomodulatory vaccine advancing to phase 3 trials highlights the evolving role of immune system recalibration in cancer treatment. From immunotherapy breakthroughs to early-stage scientific ...

Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected rangeConsented subjects now ...

The RAINIER study continues to enroll patients across additional dose levels. Mipletamig's design leverages Aptevo's ADAPTIR (TM) platform to deliver targeted T-cell engagement with the goal of ...

Data presented at ASH suggested that CDK4/6 inhibitors given with chemo for Rb-deficient tumors could mitigate the risk of secondary myeloid neoplasms.

SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results. ・Across the treated group, the overall response rate (ORR) reached 46%. ・For the ...

SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one ...

Broad tumor coverage Developed with our AI-Immunology™ platform, EVX-04 targets non-conventional ERV tumor antigens from the dark genome. These antigens are selectively expressed in specific tumors ...

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.